Today: 21 May 2026
Coinbase stock drops nearly 3% as an insider sale notice lands and traders look to a big data week
28 February 2026
2 mins read

Coinbase stock drops nearly 3% as an insider sale notice lands and traders look to a big data week

New York, February 28, 2026, 15:05 (EST) — Market closed.

Coinbase Global Inc shares fell 2.88% on Friday to close at $175.85, with the stock swinging between $171.81 and $179.06 as volume ran above 11 million shares. U.S. markets are shut through the weekend, leaving crypto prices and macro headlines to set the tone into Monday.

The move followed a noisy week for Coinbase, after the company enabled commission-free stock and ETF trading for all U.S. users, with 24-hour weekday access. Chief Executive Brian Armstrong called it a “big moment” in a social media post and said it was another step toward offering tokenized equities. Investopedia

Why it matters now: Coinbase has been trying to broaden beyond crypto trading fees, but its results still lean heavily on how much customers trade when crypto prices swing. Earlier this month it reported a surprise quarterly loss as transaction revenue slipped, even as “subscription and services” revenue rose on strength tied to stablecoins, Reuters reported. Reuters

Friday’s pullback also came as Wall Street ended lower. The S&P 500 fell 0.4% and the Nasdaq slid 0.9%, with investors weighing inflation worries and geopolitical tensions alongside a fresh debate over winners and losers in the AI buildout, the Associated Press reported.

Crypto itself did not give a clean signal into the weekend. Bitcoin last traded around $66,284 on Saturday, while ether was near $1,941 — both modestly higher on the day — but the tape has been jumpy enough that traders are still treating crypto-linked equities like a risk barometer.

Company filings added their own noise. A Form 144 filed on Friday showed Coinbase Chief Legal Officer Paul Grewal disclosed a proposed sale of 5,253 Class A shares, with an aggregate market value of about $921,114, through J.P. Morgan. A Form 144 is a required notice tied to planned resales under SEC Rule 144.

Another filing earlier in the week flagged insider selling as well. A Form 4 filed on Thursday showed Chief People Officer Lawrence Brock sold 4,821 Class A shares on Feb. 24 at weighted-average prices in the mid-$150s, under a Rule 10b5-1 plan — a pre-arranged trading plan often used by executives.

Regulatory and compliance headlines are also back in the mix for the broader sector. Tether said it had frozen about $4.2 billion of its USDT stablecoin over links to illicit activity, Reuters reported — a reminder that law enforcement pressure around crypto rails remains a live issue. (A stablecoin is a crypto token designed to track a currency such as the U.S. dollar.)

Coinbase was not alone on Friday. Robinhood Markets and Strategy ended down about 5% each, while bitcoin miner Riot Platforms was roughly flat, according to market data.

The question for Monday is whether this week’s “everything app” push translates into steadier engagement, or just adds another moving part to a stock already tethered to crypto mood swings.

But there’s an obvious downside scenario: if crypto prices sag or trading activity dries up, transaction revenue can fall fast, and product expansion does not instantly replace that lost volume. The sector’s regulatory drumbeat can also turn from background risk to headline risk in a hurry.

What investors are watching next is less about a single Coinbase headline and more about the calendar. U.S. manufacturing data are due on Monday, March 2, followed by the February jobs report on Friday, March 6 at 8:30 a.m. ET, and the February CPI release on March 11 — all potential triggers for rates and risk appetite.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Cisco stock: what to watch before Monday after CSCO closes at $79.46
Previous Story

Cisco stock: what to watch before Monday after CSCO closes at $79.46

STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead
Next Story

STI flirts with 5,000: Yangzijiang and AEM set the pace on SGX in the week ahead

Go toTop